Business StandardCenter·
Biocon arm gets supplemental USFDA approval for autoimmune disease drug
Biocon Ltd on Tuesday said its subsidiary has received supplemental approval from the US health regulator for Yesintek prefilled autoinjector. Yesintek is indicated for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. The company's subsidiary in the United States has received supplemental US Food and Drug Administration (USFDA) approval for Yesintek of strengths 45 mg/0.5 ml single-dose prefilled autoinjector and 90 mg/ml single-dose prefilled autoinjector, B…
Read at Business Standard →
